DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Follow-on drugs: Circumventing the customary patent cliffs in Big Pharma

For decades, Pharma juggernauts have been facing the challenge of patent cliffs for their blockbuster drugs. In light of the intense competition offered by generics, Big Pharma is exploring a plethora of LCM strategies to overcome the impact of patent expiry and consolidate their market position.  In this compendium we lay out five imperatives that establish the backbone of any follow-on product strategy and make it worthwhile to pursue along with live real-time case studies.